Korsana emerges with $175M to develop brain shuttle Alzheimer’s therapy
What's the deal? Korsana Biosciences has emerged from stealth with $175 million to develop a new antibody therapy for Alzheimer’s disease.
It was founded in 2024 with a $25 million seed round from FairmountDealroom has a profile for this one. Try Dealroom → and Venrock Healthcare Capital Partners, and closed a $150 million private Series A in September 2025 co-led by Wellington Management and TCGXDealroom has a profile for this one. Try Dealroom →.
Its lead programme, KRSA-028, a next-generation shuttled antibody targeting amyloid beta, was discovered in partnership with Paragon TherapeuticsDealroom has a profile for this one. Try Dealroom →. The drug uses “brain shuttles” to cross the blood-brain barrier more efficiently, aiming to clear plaques linked to memory loss.
Korsana says the approach could improve delivery and reduce risks seen with current therapies.
Why now? Approved drugs such as Leqembi and Kisunla have validated amyloid as a target but carry safety risks, including brain bleeding and swelling.
Shuttle-enabled delivery has gained attention after RocheDealroom has a profile for this one. Try Dealroom → reported four- to 18-times higher brain exposure in early studies, with under 5% rates of brain bleeds.
Korsana expects to begin clinical testing later this year.
What could go wrong? The Alzheimer’s field is crowded, and Korsana trails larger rivals already in late-stage trials. Proof-of-concept data is not expected until the second half of 2027.
Clinical development remains risky, and competition could weigh on commercial prospects.
The signal: Large venture rounds in neurodegeneration continue despite past disappointments. The focus is shifting toward safer delivery and better dosing, not just new targets.
Brain shuttle technology may define the next wave of Alzheimer’s drugs.
Sources:
Korsana Biosciences
Business Wire
Fierce Biotech
STAT
FinSMEs
J.V.
